Harvey L. Levy MD, MA

Dr. Levy directs a clinical research group that is studying the effect of innovative therapies for phenylketonuria (PKU). His group has examined the role of cofactor therapy for stimulating phenylalanine hydroxylase (PAH) and is currently a major site for a clinical trial of alternative enzyme therapy of PKU. Dr. Levy is also an investigator for the national study of the natural history and treatment of urea cycle disorders, a study examining brain imagining in PKU, and a study to determine the feasibility of next generation sequencing in newborn screening.